Literature DB >> 24106410

Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation.

Xiao-Di Yan1, Min Yao, Li Wang, Hai-Jian Zhang, Mei-Juan Yan, Xing Gu, Yun Shi, Jie Chen, Zhi-Zhen Dong, Deng-Fu Yao.   

Abstract

AIM: To investigate the dynamic features of insulin-like growth factor-I receptor (IGF-IR) expression in rat hepatocarcinogenesis, and the relationship between IGF-IR and hepatocytes malignant transformation at mRNA or protein level.
METHODS: Hepatoma models were made by inducing with 2-fluorenylacetamide (2-FAA) on male Sprague-Dawley rats. Morphological changes of hepatocytes were observed by pathological Hematoxylin and eosin staining, the dynamic expressions of liver and serum IGF-IR were quantitatively analyzed by an enzyme-linked immunosorbent assay. The distribution of hepatic IGF-IR was located by immunohistochemistry. The fragments of IGF-IR gene were amplified by reverse transcription-polymerase chain reaction, and confirmed by sequencing.
RESULTS: Rat hepatocytes after induced by 2-FAA were changed dynamically from granule-like degeneration, precancerous to hepatoma formation with the progressing increasing of hepatic mRNA or IGF-IR expression. The incidences of liver IGF-IR, IGF-IR mRNA, specific IGF-IR concentration (ng/mg wet liver), and serum IGF-IR level (ng/mL) were 0.0%, 0.0%, 0.63 ± 0.17, and 1.33 ± 0.47 in the control; 50.0%, 61.1%, 0.65 ± 0.2, and 1.51 ± 0.46 in the degeneration; 88.9%, 100%, 0.66 ± 0.14, and 1.92 ± 0.29 in the precancerosis; and 100%, 100%, 0.96 ± 0.09, and 2.43 ± 0.57 in the cancerous group, respectively. IGF-IR expression in the cancerous group was significantly higher (P < 0.01) than that in any of other groups at mRNA or protein level. The closely positive IGF-IR relationship was found between livers and sera (r = 0.91, t = 14.222, P < 0.01), respectively.
CONCLUSION: IGF-IR expression may participate in rat hepatocarcinogenesis and its abnormality should be an early marker for hepatocytes malignant transformation.

Entities:  

Keywords:  Gene amplification; Hepatoma; Immunohistochemistry; Insulin-like growth factor-I receptor; Rat hepatoma model; Sequencing

Mesh:

Substances:

Year:  2013        PMID: 24106410      PMCID: PMC3785631          DOI: 10.3748/wjg.v19.i36.6084

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.

Authors:  Hui Zhao; Vidhi Desai; Jian Wang; David M Epstein; Mark Miglarese; Elizabeth Buck
Journal:  Mol Cancer Ther       Date:  2011-12-09       Impact factor: 6.261

Review 2.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

3.  Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma.

Authors:  Chia-Jui Weng; Yi-Hsien Hsieh; Chiung-Man Tsai; Yin-Hung Chu; Kwo-Chang Ueng; Yu-Fan Liu; Yuan-Hung Yeh; Shih-Chi Su; Yi-Chen Chen; Mu-Kuan Chen; Shun-Fa Yang
Journal:  Ann Surg Oncol       Date:  2010-01-30       Impact factor: 5.344

Review 4.  Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

5.  Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma.

Authors:  D Yao; D Jiang; Z Huang; J Lu; Q Tao; Z Yu; X Meng
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

6.  Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes.

Authors:  Deng-Fu Yao; Zhi-Zhen Dong; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Hong-Mei Wang; Xian-Yong Meng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-11

Review 7.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 8.  Specific molecular markers in hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Zhi-Zhen Dong; Min Yao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-06

9.  Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis.

Authors:  Tsuneyuki Ubagai; Takane Kikuchi; Toshio Fukusato; Yasuo Ono
Journal:  Toxicol In Vitro       Date:  2009-12-29       Impact factor: 3.500

10.  A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines.

Authors:  Christian Freise; Martin Ruehl; Ulrike Erben; Ulf Neumann; Daniel Seehofer; Ki Young Kim; Wolfram Trowitzsch-Kienast; Thorsten Stroh; Martin Zeitz; Rajan Somasundaram
Journal:  BMC Complement Altern Med       Date:  2011-05-12       Impact factor: 3.659

View more
  11 in total

1.  Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C.

Authors:  Aldona Kasprzak; Agnieszka Adamek; Wiesława Przybyszewska; Przemysław Pyda; Jacek Szmeja; Agnieszka Seraszek-Jaros; Agata Lanzafame; Anna Surdacka; Iwona Mozer-Lisewska; Maria Koczorowska
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs.

Authors:  Jennifer Mitchell; Peggy T Tinkey; Rony Avritscher; Carolyn Van Pelt; Ghazaleh Eskandari; Suraj Konnath George; Lianchun Xiao; Erik Cressman; Jeffrey S Morris; Asif Rashid; Ahmed O Kaseb; Hesham M Amin; Rajesh Uthamanthil
Journal:  Oncology       Date:  2016-06-16       Impact factor: 2.935

Review 3.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

Review 4.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

5.  Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma.

Authors:  Jinjin Yan; Xinzheng Yang; Lin Li; Pengtao Liu; Honghui Wu; Zhanao Liu; Qingyi Li; Guozhen Liao; Xinlong Wang
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

Review 6.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

7.  High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Wenjie Zheng; Junling Yang; Zhizhen Dong; Li Wang; Miao Fang; Wei Wu; Dengfu Yao; Min Yao
Journal:  Cancer Manag Res       Date:  2018-11-20       Impact factor: 3.989

8.  Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma.

Authors:  Wenjie Zheng; Min Yao; Miao Fang; Liuhong Pan; Li Wang; Junling Yang; Zhizhen Dong; Dengfu Yao
Journal:  J Cancer       Date:  2019-10-08       Impact factor: 4.207

9.  Correlation Between IGFs-Related Proteins Expression and Incidence of Colorectal Cancer in Diabetic Patients and Related Mechanisms.

Authors:  Xu Han; Sufang Hou; Aige Yang
Journal:  Med Sci Monit       Date:  2016-03-15

10.  Abnormal expression of HMGB-3 is significantly associated with malignant transformation of hepatocytes.

Authors:  Wen-Jie Zheng; Min Yao; Miao Fang; Li Wang; Zhi-Zhen Dong; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.